Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunc... (ecutive officer. Dr. Ueno foundedSucampo...)

HOME >> MEDICINE >> TECHNOLOGY

Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)

Date:9/13/2007

ecutive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding CEO and advisor, international business development. Sucampo Pharmaceuticals' first product, AMITIZA(R), received marketing approval from the U.S. Food and Drug Administration in January 2006 for the treatment of Chronic Idiopathic Constipation in adults. AMITIZA is co-promoted in the United States and Canada through an alliance between Sucampo Pharmaceuticals and Takeda Pharmaceutical Company Limited (Osaka, Japan). Sucampo Pharmaceuticals' sales force targets the institutional marketplace, including academic medical centers and long- term care facilities, while Takeda focuses on office-based specialty and primary care physicians. To learn more about Sucampo Pharmaceuticals and its products, visit http://www.sucampo.com.

Takeda Pharmaceuticals North America, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets products for diabetes, insomnia, wakefulness and gastroenterology. The company has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit http://www.tpna.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Sucampo Pharmaceuticals, Inc. are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words "project," "believe," "anticipate," "plan,"
'/>"/>

SOURCE Sucampo Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial

Post Your Comments:

(Date:12/15/2009)... -- OrthoWorx, the newly formed industry, community and education ... in Kosciusko County, is working to connect the orthopedics ... and Cleveland via high-speed rail. ,, In a September ... Capital of the World -- An overview, analysis ... BioCrossroads, the statewide initiative to grow Indiana,s unique ...

(Date:12/15/2009)... Ever wonder what something looks like up ... of the Personal Scanning Electron Microscope (PSEM), kicked off ... send in samples to be scanned by one of ... scan range of 100nm to 5mm and an imaging ... into focus. In addition, ASPEX will not only scan ...

(Date:12/15/2009)... DURHAM, N.C., Dec. 15 A Harvard medical ... testosterone says that the PGA Tour,s decision last ... Barron,s doctor had diagnosed him as having the ... Barron for this condition is "unreasonable, unfair and ... of lower than normal testosterone levels, often referred ...

Breaking Medicine Technology:OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 2 OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland 3 ASPEX Kicks Off Free 'Send Us Your Sample' Microscopy Campaign 2 Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2 Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3 Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4 Negative Pressure Wound Devices Draw FDA Notice Advice 6906 1 Negative Pressure Wound Devices Draw FDA Notice Advice 6906 2 Linguists to gather in Baltimore for national conference 63062 1 Linguists to gather in Baltimore for national conference 63062 2 Linguists to gather in Baltimore for national conference 63062 3 Fighting IED attacks with SCARE technology 11088 1 Fighting IED attacks with SCARE technology 11088 2 Fighting IED attacks with SCARE technology 11088 3

[0] OrthoWorx Urges Warsaw's Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland [0] ASPEX Kicks Off Free 'Send Us Your Sample' Microscopy Campaign [0] Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory'

... of patients with acute coronary syndrome being managed ... ... TOKYO and INDIANAPOLIS, Feb. 21 Daiichi,Sankyo Company, Limited (TSE: ... that the U.S. Food and Drug Administration (FDA) accepted,and designated Priority ...

... DIEGO, Feb. 21 Gen-Probe Incorporated,(Nasdaq: GPRO ) ... (FDA),a supplemental regulatory application for the additional use of ... hepatitis B,virus (HBV), the Company announced today. The FDA ... the hepatitis C virus (HCV) in late,2006., The ...

Other Medicine Technology:FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel 2 FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel 3 Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 2 Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 3 Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 4

FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay

(Date:12/15/2009)... BALTIMORE, Dec. 15 SUMMARY: ... the Patient Protection and Affordable Care Act that ... by allowing for the safe and legal importation ... amendment, endorsed by AARP and sponsored by Senators ... improved competition and helped to bring down the ...

(Date:12/15/2009)... of coal for lying about taxes in the healthcare bill ... Baucus has earned a place under the "Naughty" column on ... after being caught telling a brazen lie on the ... healthcare bill would not raise taxes. ,, Speaking on ... " I have also heard ...

(Date:12/15/2009)... of leptin associated with lower dementia risk, research finds ... levels of leptin, a hormone that regulates appetite, may ... in 10 or 15 years this may be one ... risk of Alzheimer,s disease," said senior study author Dr. ... University School of Medicine. "Or it may be one ...

(Date:12/15/2009)... education program will train advocates to be leaders ... Project developed with support from experts in online ... ,, WASHINGTON, Dec. 15 ... are accepting applications for the first-ever "Malaria Griots" ... and educate participants to become leaders in the ...

(Date:12/15/2009)... The following are the remarks by ... criminal division, at the Medicare Fraud Strike Force ... thank you for the enormous effort everyone at ... ,, Together, our Departments have and will continue ... made tremendous progress in fighting Medicare fraud in ...

Breaking Medicine News(10 mins):Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2 Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3 Health News:ATR: Baucus Earns Place on 2009 "Naughty" List 2 Health News:ATR: Baucus Earns Place on 2009 "Naughty" List 3 Health News:Fat Hormone May Protect Against Alzheimer's 2 Health News:Fat Hormone May Protect Against Alzheimer's 3 Health News:ONE and Malaria No More Launch 'Malaria Griots' 2 Health News:ONE and Malaria No More Launch 'Malaria Griots' 3 Health News:ONE and Malaria No More Launch 'Malaria Griots' 4 Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 2 Health News:Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference 3

[0] AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices [0] ATR: Baucus Earns Place on 2009 "Naughty" List [0] Fat Hormone May Protect Against Alzheimer's [0] ONE and Malaria No More Launch 'Malaria Griots'[1] Remarks by Lanny A. Breuer, Assistant Attorney General for the Criminal Division, at the Medicare Fraud Strike Force Press Conference

... (Washington) "The benefits of widespread adoption of interoperable ... to a higher standard of quality in the U.S. ... House Ways and Means Committee subcommittee on Health today. ... their patients will be left behind the technological curve." ...

... Immunochemist Mark C. Swanson got,leading scientists and ... a bright future for natural rubber latex (NRL) ... of Vytex(TM),NRL from Vystar Corporation. This commercially available ... as raw material while,preserving desirable NRL properties in ...

... research facility is planned to enable unprecedented understanding of ... human behaviour. The 28.5 million funding comes from ... and Skills (DIUS), and will be used for the ... a collaboration between the Economic and Social Research Council ...

... annual Retail Business Conference, company launches exclusive brand, ... outbound ... technology, ORLANDO, Fla., July 24 As consumerism, ... the way health care is delivered, Cardinal Health today ...

... The board of,directors for Hillenbrand, Inc. (NYSE: ... million of the company,s outstanding common shares. Purchases,will be ... or in privately,negotiated transactions, and will be funded from ... decision to implement a share repurchase program for our,new ...

... $0.38 in ... Record diluted EPS increased 30.2 percent to $0.56 from $0.43 in, second-quarter 2007, excluding $0.05 in ... from the 2003 spin-off ... - Specialty revenues increased 32.6 percent to a record of nearly $2.0 ...

ACP says Medicare should increase payments for physicians that use HIT to improve quality Vytex(TM) Natural Rubber Latex Manufacturing Test Results Get International Latex Conference Buzzing £28.5M investment for groundbreaking new research facility Cardinal Health Expands Leader(R) Offering To Help Independent Pharmacies Strengthen Patient Relationships, Solidify Role As Local Health Care Experts Hillenbrand, Inc. Board of Directors Approves $100M Share Repurchase Program Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance

... improved OrthoWedge® Healing Shoe offers the most ... forefoot while allowing patients to maintain their ... wedge, an even larger portion of the ... the metatarsal heads and toes to heal ...

Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....

... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...

... is a given with our High Beam TriLens ... and remarkably brilliant 11.5 cm spot at a ... its class. , ,To achieve this unequaled performance ... with three of the finest Mag-Fluoride coated lenses ...

Medicine Products:

OrthoWedge Healing Shoes Polycast Cast Boot Gliadin IgG Kit High Beam TriLens Classic and Sport

Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunc...(ecutive officer. Dr. Ueno foundedSucampo...),Health